Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Aiso, Tokyo

Keiichi Aiso, Tokyo JP

Patent application numberDescriptionPublished
20080298759OPTICAL FIBER AND OPTICAL WAVEGUIDE - An optical fiber includes a core region having a first refractive index and a cladding region having a second refractive index lower than the first refractive index on an outer circumference of the core region. The cladding region includes four holes formed to have a four-fold rotational symmetry with respect to a center axis around the core region in a longitudinal direction, such that a zero-dispersion wavelength is 900 nm to 1150 nm and a cutoff wavelength is equal to or shorter than 950 nm.12-04-2008
20100239217OPTICAL FIBER AND OPTICAL WAVEGUIDE - An optical fiber includes a core region having a first refractive index and a cladding region having a second refractive index lower than the first refractive index on an outer circumference of the core region. The cladding region includes four holes formed to have a four-fold rotational symmetry with respect to a center axis around the core region in a longitudinal direction, such that a zero-dispersion wavelength is 900 nm to 1150 nm and a cutoff wavelength is equal to or shorter than 950 nm.09-23-2010

Patent applications by Keiichi Aiso, Tokyo JP

Sadakazu Aiso, Tokyo JP

Patent application numberDescriptionPublished
20080227699Therapeutic Agent for Neurodegenerative Diseases - The present invention relates to a pharmaceutical composition for the treatment and/or prevention of a neurodegenerative disease, comprising the following polypeptide shown in any of (a) to (c): (a) a polypeptide comprising the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1); (b) a polypeptide comprising an amino acid sequence having a deletion, substitution, insertion, and/or addition of one or several amino acids in the amino acid sequence consisting of Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death associated with neurodegenerative disease; and (c) a modified polypeptide from the polypeptide (a) or (b), or a pharmaceutically acceptable salt thereof, as an effective ingredient.09-18-2008
20090075900Therapeutic agent for motor neuron disease - An object of the present invention is to provide an agent effective for the treatment and/or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and/or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to (c) or a pharmaceutically acceptable salt thereof as an active ingredient: (a) an oligopeptide consisting of the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1); (b) an oligopeptide consisting of an amino acid sequence having a deletion, substitution, insertion, or addition of one or several amino acids in Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death caused by a mutant superoxide dismutase-1 gene; and (c) a modified oligopeptide from the oligopeptide (a) or (b).03-19-2009
20100223684HUMANIN RECEPTOR OR HUMANIN-LIKE POLYPEPTIDE RECEPTOR - One aspect of the present invention is directed to search receptors based on the information of HN signaling pathways in order to find Humanin receptor or Humanin-like polypeptide receptor (HNR), and to reveal a mechanism of promoting or suppressing the intracellular signal transduction for neuroprotecting activity of HN and identify a compound involved in the mechanism. The aspect of the invention is directed to a method for screening of HNR agonist and HNR antagonist, to utilize the screened compound in development of a drug for the treatment of neurodegenerative disease, and to provide an assay system of AD neuronal cell death, and to provide methods for the compulsory expression of HNR gene or knocking-out of intracellular genes.09-02-2010
20100279942METHODS FOR TREATING MOTOR NEURON DISEASE - An object of the present invention is to provide an agent effective for the treatment and/or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and/or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to (c) or a pharmaceutically acceptable salt thereof as an active ingredient: (a) an oligopeptide consisting of the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1); (b) an oligopeptide consisting of an amino acid sequence having a deletion, substitution, insertion, or addition of one or several amino acids in Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death caused by a mutant superoxide dismutase-1 gene; and (c) a modified oligopeptide from the oligopeptide (a) or (b).11-04-2010

Patent applications by Sadakazu Aiso, Tokyo JP

Toshiharu Aiso, Tokyo JP

Patent application numberDescriptionPublished
20110002807STEEL FOR INDUCTION HARDENING - This steel for induction hardening includes: in terms of mass %, C: 0.40% or more to 0.75% or less; Si: 0.002% or more to 3.0% or less; Mn: 0.20% or more to 2.0% or less; S: 0.002% or more to 0.1% or less; Al: more than 0.10% to 3.0% or less; P: 0.030% or less; and N: 0.035% or less, with the remainder being Fe and inevitable impurities.01-06-2011